New study


Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these women. The Viennese company has begun a further clinical trial at the University of Graz with 20 patients that have received radiation after breast surgery. APN201 was developed by Polymun Scientific AG, another biotech company based in Vienna. Apeiron in­licensed the compound, which has already completed several clinical trials, the most advanced in Phase II. The human enyzme superoxide dismutase is essential for protecting human cells from damage by reactive oxygen species that are created through radiation.

Politics / Law


London – The European Medicines Agency (EMA) will publish information about all drugs under review, beginning on March 1. On a monthly basis the company will issue a list disclosing the international non-proprietary name and...

Politics / Law


Brussels – The European Commission has adopted a strategy to set the European economy on a biological base. "Europe needs to make the transition to a post-petroleum economy", said Commissioner for Research, Innovation and Science...

Politics / Law


Brusssels/Manila - The acreage of GM crops is on the rise worldwide - even in Europe. Roughly 160 million hectares were planted with biotech crops in 2011, up 8 per cent from 2010, the International Service for the Acquisition of...

Politics / Law


London/Brussels - The exodus of plant biotechnology out of Europe seems to have accelerated. Just three weeks ago, BASF Plant Science announced it would leave Europe as an R&D location for developing its GM plants. But now,...

Politics / Law


Brussels – Predicting the future is often not more than a guessing game. But two signs recently appeared on the horizon which indicate that the biotechnology industry will play a dominant role in the dynamics of EU economics in...



Innsbruck/Brussels - Twelve institutions in seven countries are working together to learn more about how one of the deadliest cancers interacts with its environment. The consortium OPTATIO (OPtimizing TArgets and Therapeutics In...

Tech Review


After years of strong double-digit value growth, the biologics market has recently stuttered, seeing year-on-year growth fall below 10%. As product space grows increasingly crowded, future success will depend on opening up the...

Tech Review


Until a decade ago, the United States was the undisputed leader in bioscience industry development. Global competition within the industry has dramatically increased – fueled in large part by low-cost labor, the speed of...

Politics / Law


London – The EMA has proposed revising its guidelines for biosimilar products. In mid-November the Agency said that the current “conceptual” guidelines – which date back to 2005, when no bio­similar products were marketed in the...

Tech Review


Denmark’s tradition of successful pharmaceutical companies and clinical trials stretches back more than a century, and over the past decade the country has emerged as a major global player in the field of biotech research.Denmark...

Displaying results 31 to 40 out of 1983

< Previous 31-40 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



All Events

Stock list

All quotes


  • NORDIC NANOVECTOR (N)24.00 NOK23.71%
  • TRANSGENE (F)4.72 EUR23.56%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%


  • THROMBOGENICS (B)3.09 EUR-20.97%
  • ZELTIA (E)3.35 EUR-12.76%
  • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%


  • KARO BIO (S)38.50 SEK2383.9%
  • TRANSGENE (F)4.72 EUR63.9%


  • THROMBOGENICS (B)3.09 EUR-42.4%
  • WILEX (D)2.05 EUR-41.4%
  • BIONOR PHARMA (N)1.26 NOK-39.4%


  • KARO BIO (S)38.50 SEK4595.1%
  • ADOCIA (F)87.65 EUR439.1%
  • GALAPAGOS (B)54.02 EUR324.7%


  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.84 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015

Current issue

All issues